Human respiratory syncytial virus diversity and epidemiology among patients hospitalized with severe respiratory illness in South Africa, 2012–2015

Ziyaad Valley-Omar1,2 | Stefano Tempia3,4,5,6 | Orienka Hellferscee1 |
Sibongile Walaza1,6 | Ebrahim Variava6 | Halima Dawood7,8 | Kathleen Kahn1 |
Meredith McMorrow3,4 | Marthi Pretorius1,9 | Senzo Mtshali1 |
Ernest Mamorobela1 | Nicole Wolter1,6 | Marietjie Venter1,10 |
Anne von Gottberg1,6 | Cheryl Cohen1,6 | Florette K. Treurnicht6,11

1National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa
2University of Cape Town, Cape Town, South Africa
3Centers for Disease Control and Prevention, Pretoria, South Africa
4Centers for Disease Control and Prevention, Atlanta, Georgia, USA
5MassGenics, Duluth, Georgia, USA
6University of the Witwatersrand, Johannesburg, South Africa
7University of KwaZulu-Natal, KwaZulu-Natal, South Africa
8Greys hospital, Pietermaritzburg, South Africa
9Novartis Pharma AG, Basel, Switzerland
10University of Pretoria, Pretoria, South Africa
11National Health Laboratory Service, Charlotte Maxeke Johannesburg Academic Hospital, Johannesburg, South Africa

Correspondence
Cheryl Cohen, National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa.
Email: cherylc@nicd.ac.za
Ziyaad Valley-Omar, National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa.
Email: z.valley-omar@uct.ac.za

Funding information
Centers for Disease Control and Prevention, Grant/Award Numbers: 5U19GH000622, 5U51IP000528

Abstract

Background: We aimed to describe the prevalence of human respiratory syncytial virus (HRSV) and evaluate associations between HRSV subgroups and/or genotypes and epidemiologic characteristics and clinical outcomes in patients hospitalized with severe respiratory illness (SRI).

Methods: Between January 2012 and December 2015, we enrolled patients of all ages admitted to two South African hospitals with SRI in prospective hospital-based syndromic surveillance. We collected respiratory specimens and clinical and epidemiological data. Unconditional random effect multivariable logistic regression was used to assess factors associated with HRSV infection.

Results: HRSV was detected in 11.2% (772/6908) of enrolled patients of which 47.0% (363/772) were under the age of 6 months. There were no differences in clinical outcomes of HRSV subgroup A-infected patients compared with HRSV subgroup B-infected patients but among patients aged <5 years, children with HRSV subgroup A were more likely be coinfected with *Streptococcus pneumoniae* (23/208,
In young children and infants, human respiratory syncytial virus (HRSV) is one of the predominant causes of acute respiratory tract illness. Globally, it was estimated that among children aged <5 years, 33.1 million episodes of HRSV-associated severe acute respiratory illness (SARI) resulted in approximately 3.2 million (95% confidence interval [CI] 2.7–3.8 million) hospitalizations and 59,600 (95% CI 48,000–74,500) in-hospital deaths in 2015; 99% of mortalities occurred in developing countries.1 Among South African patients admitted to sentinel surveillance hospitals for SARI, HRSV detection rates of 27% (1157/4293) and 4% (329/7796) were reported for children aged <5 years (2010–2011) and adults aged >18 years (2009–2013), respectively.2,3 Within these populations, HIV coinfection was found to negatively affect disease outcomes including increased odds of hospitalization.2

HRSV is divided into two phylogenetically distinct subgroups (HRSV A and B), and these are further classified into multiple distinct genotypes based on sequence variability in the C-terminus of the envelope glycoprotein G (G protein).4–7 Since 2002, novel genotype BA, and since 2009 novel genotype ON1, displaying 60- and 72-nucleotide sequence duplications (HRSV subgroups B and A, respectively) within the second variable domain of the C-terminus have emerged.4–7,10–13 To date, these novel genotypes have disseminated globally, becoming the dominant genotypes in circulation.4–7,10–14 Contrasting findings have found no clear consensus between HRSV subgroups/genotypes and clinical outcomes.4,7–12,15 Inconsistencies observed between studies may be due to small sample sizes and geographic variances in population diversity and herd immunity, which could predispose to or protect individuals from adverse clinical outcomes.

While no HRSV vaccines are currently available, global HRSV surveillance aided the development of multiple vaccine candidates that are in various stages of evaluation.16 The high degree of sequence variance and complex circulation patterns of HRSV resulted in challenges for development of an effective HRSV vaccine.13,16–19 These challenges include global and regional gaps in knowledge of HRSV epidemiology, subgroup and genotype geographic circulation patterns, target patient demographics, and outcomes for HRSV-associated clinical illness.16 Regular updates of these knowledge gaps provide an information baseline that can be used to evaluate regional vaccine effectiveness when implemented and can inform vaccine formulation suitability and timing.

In this study, we aimed to describe the seasonal patterns and prevalence of HRSV subgroups and genotypes among hospitalized patients with severe respiratory illness (SRI) in South Africa, from 2012 through 2015. We also aimed to compare the associations of HRSV subgroups and genotypes with epidemiologic characteristics and clinical outcomes.

## METHODS

### 2.1 Study design and population

We enrolled participants in a prospective hospital-based SRI surveillance program from 01 January 2012 through 31 December 2015 at Edendale and Klerksdorp-Tshepong Hospitals situated in periurban areas in the subtropical KwaZulu-Natal and temperate North West Provinces of South Africa, respectively. The SRI case definition included hospitalized individuals of any age with illness onset of any duration prior to admission meeting age-specific inclusion criteria. Children aged 2 days to <3 months included any hospitalized patient with diagnosis of suspected sepsis or physician-diagnosed lower respiratory tract infection.20 Children aged 3 months to <5 years included any hospitalized patient with physician-diagnosed lower respiratory tract infection, including bronchitis, bronchiolitis, pneumonia, and pleural effusion.20 Individuals aged ≥5 years included any hospitalized patient presenting with lower respiratory tract infection with temperature ≥38°C or history of fever and cough.20 A case investigation form that included clinical details (fever ≥38°C, cough, requirement for supplemental oxygen, prolonged hospitalization ≥5 days, in-hospital death, admission to ICU, tachypnea, stridor) and underlying medical conditions (HIV infection, prematurity, heart disease, malnutrition, chronic lung disease, and asthma) was completed for all enrolled patients.

### 2.2 Sample collection

Respiratory samples (nasopharyngeal aspirates for children <5 years of age and combined nasopharyngeal and oropharyngeal swabs from
individuals ≥5 years of age) were collected and placed in universal transport medium (Copan, California, USA), stored at 4°C–8°C and transported within 72 h of collection to the National Institute for Communicable Diseases (NICD), Johannesburg, South Africa, for testing. Whole blood samples (EDTA) were collected from consenting patients for the detection of Streptococcus pneumoniae (S. pneumoniae) by lytA polymerase chain reaction (PCR).

2.3 Determination of HIV status

HIV infection status was obtained from a combination of two sources: (i) patient clinical records and (ii) for consenting patients, dried blood spots that were tested by enzyme-linked immunosorbent assay (ELISA) for patients aged ≥18 months and PCR for children aged <18 months if the ELISA was reactive or exposure status was unknown.

2.4 Laboratory detection of HRSV

Samples collected from 2012 through 2014 were tested for the presence of HRSV and other respiratory viruses (influenza A and B viruses, parainfluenza virus [PIV] types 1–3, adenoviruses, rhinoviruses, human metapneumovirus [hMPV], and enteroviruses) using an in-house multiplex real-time reverse transcription PCR (rt-RTPCR) assay. From 2015, a validated commercial one-step multiplex rt-RTPCR assay, FTD® Flu-HRSV kit (FastTrack Diagnostics, Luxembourg), was used for the detection of HRSV and influenza A and B viruses. The 2015 samples were also tested for adenoviruses, enteroviruses, parainfluenza viruses (PIV) types 1–4, human metapneumovirus (hMPV), and rhinoviruses as before but now human bocaviruses and seasonal human coronaviruses types (NL63, 229E and OC43) were included in our testing panel using the Allplex one-step rt-RTPCR respiratory panels 2 and 3 (Seegene, Seoul, Korea).

2.5 Determination of HRSV A/B subgroup by real-time reverse transcription PCR

HRSV subgroup was determined on all subgrouped samples using an in-house one-step rt-RTPCR designed for the detection of HRSV A and HRSV B using previously published methods.

2.6 Amplification and sequencing of the HRSV G protein gene

The complete HRSV G-protein gene was PCR-amplified following random primer cDNA synthesis using the SuperScript III reverse transcriptase kit (Invitrogen, Life Technologies). The second round PCR utilized the G32A(HRSV A), G598A(HRSV A)/G32B(HRSV B), G604B(HRSV B) forward, or G665R and F1 reverse primers as described. HRSV-positive samples with insufficient volume or positives with cycle threshold (Ct)-values of >35 were not PCR amplified for sequencing as they were unlikely to successfully amplify. PCR products were analyzed and viewed following gel electrophoresis on a 1% agarose gel and purified using the Wizard® SV Gel and PCR Clean-Up System (Promega Corporation, Madison, WI, USA). Cycle sequencing was performed with the BigDye terminator 3.1 cycle sequencing kit (Applied Biosystems, Foster City, CA, USA). Sequences were assembled using Sequencher® version 5 (Gene Codes Corporation, Michigan, USA). Sequences with the following accession numbers MN516831 to MN517111 were uploaded to GenBank.

2.7 Phylogenetic analysis of HRSV partial G protein genes

Unique HRSV A and HRSV B virus G-gene nucleotide sequences representing the second variable domain (330 base pairs: nucleotides 5323–5652) were aligned separately using Multiple Sequence Comparison by Log Expectation (MUSCLE), along with unique international genotype reference sequences (accession numbers shown in Figure 3), downloaded from the GenBank sequence database, using default settings. As the GenBank database predominantly contains partial HRSV G protein gene sequences spanning the second variable domain; this was the gene region selected for partial sequence G-protein alignments in this analysis. Phylogenies were determined by the construction of maximum likelihood phylogenetic trees using RaxML (Heidelberg Institute for Theoretical Studies, Heidelberg, Germany) with the GTR-GAMMA nucleotide substitution model with branch support assessed with 100 bootstrap replicates.

2.8 Statistical analysis

Unconditional logistic regression was used to assess factors associated with HRSV-positivity and factors associated with HRSV A and HRSV B-positivity among individuals hospitalized with SRI aged <5 years and ≥5 years separately. We assessed factors associated with commonly identified genotypes, ON1 and NA1 among HRSV-positive patients aged <5 years with available genotype results. We further assessed factors associated with presence of fever among HRSV-positive patients of all ages. A random effect on admission facility was included for all analysis to account for potential differences in the service population. Variables for which the p value in univariate analysis was ≤0.2 were assessed in multivariable models by forward selection and statistical significance was assessed at p < 0.05. The analysis was performed using STATA 14.1 (StataCorp, College Station, TX, USA).
2.9 | Ethical considerations

The SRI surveillance protocol was reviewed and approved by the University of the Witwatersrand Human Research Ethics Committee (HREC; protocol number M081042), the University of KwaZulu Natal, Human Biomedical Research Ethics Committee (BREC) protocol number BF157/08. This surveillance protocol was reviewed and deemed nonresearch (number 2012-6197) by the US Centers for Disease Control and Prevention (CDC, Atlanta, Georgia, USA).

3 | RESULTS

3.1 | Study population

From 2012 through 2015, we enrolled 6910 patients with SRI of which 6908 (>99.9%) had available laboratory test results and were included in the analysis. Of these, 36.3% (2509/6908) were children aged <5 years (Table 1) and 49.6% (3421/6897) were female. HIV results were available for 94.1% (6498/6908) of patients of whom 51.9% (3372/6498) were HIV infected. The HIV prevalence was lowest (10.1%; 143/1417) among infants aged <1 year and highest (90.5%; 1884/2081) among individuals aged 25–44 years.

3.2 | HRSV detection

During the study period, HRSV was detected in 11.2% (772/6908) of samples, 24.0% (601/2509) among individuals aged <5 years and 3.9% (171/4399) among individuals ≥5 years of age. Of the 772 HRSV-infected patients, 47.0%, (363/772) were <6 months of age. Year-round HRSV activity was observed across the 4-year observation period with a surge of HRSV activity observed each year between March and May (autumn) (2012–2015) resulting in a single peak per year (Figure 1). An apparent second peak or surge of HRSV activity was noted between September and December of 2012 (Spring–Summer). This second peak was only observed for patients admitted to Edendale Hospital located in the KwaZulu-Natal Province of South Africa (Figure S1).

3.3 | Factors associated with HRSV-positivity in patients hospitalized with SRI

On multivariable analysis considering clinical presentation, underlying medical conditions and coinfection variables among persons aged <5 years, a higher odds of HRSV infection was associated with younger age groups when compared to individuals aged 24–59 months (<3 months adjusted odds ratio [aOR]: 4.5; 3–5 months aOR: 3.4; 6–11 months aOR: 2.0; 12–23 months aOR: 1.6). In addition, HRSV-positive children were more likely to present with temperature ≥38°C (aOR: 1.3), have a cough (aOR: 7.6), and receive oxygen support during admission (aOR: 1.4) (Table 1). HRSV-positive children were less likely to be admitted to the intensive care unit (ICU) (aOR: 0.4), to be malnourished (aOR: 0.5), be HIV infected (aOR: 0.4), and be coinfected with influenza viruses (aOR: 0.2), rhinoviruses (aOR: 0.4), enteroviruses (aOR: 0.6), hMPV (aOR: 0.1), and PIV 1–3 (aOR: 0.2) than HRSV-negative children (Table 1). HRSV positive persons aged <5 years, persons aged ≥3 months were more likely to present with fever when compared to those <3 months (3–5 months aOR: 2.2, 95% CI: 1.7–2.8; 6–11 months aOR: 2.9, 95% CI: 2.3–3.8; 12–23 months aOR: 3.2, 95% CI: 2.4–4.1; 24–59 months aOR: 2.8, 95% CI: 2.2–3.7) (data not shown).

HRSV-positive individuals ≥5 years were more likely to be HIV infected (aOR: 1.6) and to be coinfected with enteroviruses (aOR: 7.3) than HRSV-negatives children aged <5 years (Table 2).

3.4 | HRSV subgroup detection and factors associated with HRSV subgroups among HRSV-positive patients hospitalized with SRI

About two thirds, 67.2% (519/772) of HRSV-positive samples, were subgrouped, of which 71.1% (369/519) were HRSV A. HRSV A was the predominate subgroup across all years except 2014 (2012: 68.8%, 2013: 90.3%, and 2015: 67.5%) (Figure 1). Similar proportions of HRSV A (45.8%, 44/96) and HRSV B (54.2%, 52/96) were seen in 2014. HRSV A positive patients <5 years were more likely to be coinfected with S. pneumoniae (aOR: 5.7), but there were no clinical differences (Table 3). No statistically significant differences were found between HRSV A and HRSV B positive individuals aged ≥5 years (Table S1).

3.5 | HRSV genotype prevalence and factors associated with HRSV genotypes among HRSV-positive patients hospitalized with SRI

Among the 519 HRSV A/B-subgrouped specimens, 33.7% (175/519) of HRSV positives (A: 82.3% [144/175]; B: 17.7% [31/175]) were sequenced and included for phylogenetic analysis. A total of 18.7% (144/519) and 30.1% (156/519) were excluded from G-protein amplification and sequencing due to low nucleic acid concentration (Ct value >35) and insufficient specimen volume, respectively, whereas 8.5% (44/519) of specimens yielded low quality, unusable sequence data.

The HRSV A genotype NA1 predominated in 2012 (94% [50/53]) and 2013 (89% [57/64]), and ON1 in 2015 (81% [22/27]) (Figure 2). HRSV B genotypes BA9 and BA10 circulated concurrently with HRSV A genotypes in 2012–2015. Five HRSV B positives genotyped in 2014 were all genotype BA10. HRSV A ON1 lineages 1.1, 1.2, and 1.3 were circulating in 2012–2013 (89% [57/64]), and ON1 in 2015 (81% [22/27]) (Figure 2).
TABLE 1 Factors associated with HRSV infection among children aged <5 years, hospitalized with severe respiratory illness, Edendale and  
Klerksdorp-Tshepong hospitals, South Africa, 2012–2015

| Characteristic                          | HRSV positive n/N (%) | HRSV negative n/N (%) | Univariate odds ratio (95% CI) | p value | Multivariable adjusted odds ratio (95% CI) ≤ 5 years | p value |
|-----------------------------------------|-----------------------|-----------------------|-------------------------------|---------|-----------------------------------------------------|---------|
| Total                                   | 601/2509 (23.9)       | 1908/2509 (76.1)      |                               |         |                                                     |         |
| Age                                     |                       |                       |                               |         |                                                     |         |
| <3 months                               | 229/601 (38.1)        | 360/1908 (18.9)       | 4.8 (3.5–6.7)                 | <0.001  | 4.5 (3.0–6.9)                                       | <0.001  |
| 3–5 months                              | 134/601 (22.3)        | 306/1908 (16.0)       | 3.3 (2.4–4.7)                 | <0.001  | 3.4 (2.2–5.2)                                       | <0.001  |
| 6–11 months                             | 106/601 (17.6)        | 404/1908 (21.2)       | 2.0 (1.4–2.8)                 | <0.001  | 2.0 (1.3–3.1)                                       | 0.001   |
| 12–23 months                            | 78/601 (13.0)         | 427/1908 (22.4)       | 1.4 (1.0–2.0)                 | 0.083   | 1.6 (1.1–2.6)                                       | 0.024   |
| 24–59 months                            | 54/601 (9.0)          | 411/1908 (21.5)       | Reference                     |         | Reference                                           | -       |
| Female                                  | 256/600 (42.7)        | 844/1907 (44.3)       | 0.9 (0.8–1.1)                 | 0.493   |                                                     |         |
| Year                                    |                       |                       |                               |         |                                                     |         |
| 2012                                    | 188/601 (31.3)        | 521/1908 (27.3)       | Reference                     |         |                                                     |         |
| 2013                                    | 165/601 (27.5)        | 590/1908 (30.9)       | 0.8 (0.6–0.9)                 | 0.037   |                                                     |         |
| 2014                                    | 133/601 (22.1)        | 401/1908 (21.0)       | 0.9 (0.7–1.2)                 | 0.521   |                                                     |         |
| 2015                                    | 115/601 (19.1)        | 396/1908 (20.8)       | 0.8 (0.6–1.1)                 | 0.110   |                                                     |         |
| Clinical presentation and course        |                       |                       |                               |         |                                                     |         |
| Fever ≥38°C                              | 370/598 (61.9)        | 1219/1896 (64.3)      | 0.9 (0.7–1.1)                 | 0.284   | 1.3 (1.0–1.7)                                       | 0.035   |
| Cough                                   | 581/596 (97.5)        | 1615/1890 (85.4)      | 6.6 (3.9–11.2)                | <0.001  | 7.6 (4.2–13.7)                                      | <0.001  |
| Supplemental oxygen needed               | 409/599 (68.3)        | 1008/1889 (53.4)      | 1.9 (1.5–2.3)                 | <0.001  | 1.4 (1.1–1.8)                                       | 0.002   |
| Prolonged hospitalization (≥5 days)     | 302/601 (50.2)        | 913/1908 (47.9)       | 1.1 (0.9–1.3)                 | 0.305   |                                                     |         |
| In-hospital death                       | 4/597 (0.7)           | 29/1883 (1.54)        | 0.4 (0.1–1.2)                 | 0.082   |                                                     |         |
| Admitted to ICU                         | 24/598 (4.0)          | 80/1887 (4.2)         | 0.9 (0.6–1.5)                 | 0.809   | 0.4 (0.2–0.8)                                       | 0.012   |
| Tachypnea                               | 335/595 (56.3)        | 879/1880 (46.8)       | 1.5 (1.2–1.8)                 | <0.001  |                                                     |         |
| Stridor                                 | 121/595 (20.3)        | 324/1878 (17.3)       | 1.2 (0.9–1.5)                 | 0.091   |                                                     |         |
| Underlying medical conditions           |                       |                       |                               |         |                                                     |         |
| HIV infection                           | 32/549 (5.8)          | 246/1756 (14.0)       | 0.4 (0.3–0.6)                 | <0.001  | 0.4 (0.3–0.6)                                       | <0.001  |
| Prematurity                             | 68/600 (11.3)         | 257/1907 (13.5)       | 0.8 (0.6–1.1)                 | 0.167   |                                                     |         |
| Heart disease                           | 1/600 (0.2)           | 5/1906 (0.3)          | 0.6 (0.07–5.44)               | 0.663   |                                                     |         |
| Malnutrition                            | 92/534 (17.2)         | 469/1746 (26.9)       | 0.6 (0.4–0.7)                 | <0.001  | 0.5 (0.4–0.7)                                       | <0.001  |
| Chronic lung disease                    | 1/600 (0.2)           | 3/1905 (0.2)          | 1.1 (0.11–10.2)               | 0.961   |                                                     |         |
| Asthma                                  | 7/600 (1.2)           | 27/1906 (1.4)         | 0.8 (0.4–1.9)                 | 0.639   |                                                     |         |
| Coinfection                             |                       |                       |                               |         |                                                     |         |
| Tuberculosis                            | 6/150 (4)             | 24/559 (4.3)          | 0.9 (0.4–2.3)                 | 0.873   |                                                     |         |
| Streptococcus pneumoniae                | 35/404 (8.7)          | 151/1348 (11.2)       | 0.8 (0.5–1.1)                 | 0.138   |                                                     |         |
| Influenza A/B                           | 10/601 (1.7)          | 130/1908 (6.8)        | 0.2 (0.1–0.4)                 | <0.001  | 0.2 (0.1–0.4)                                       | <0.001  |
| Rhinovirus                              | 154/601 (25.6)        | 763/1908 (40.0)       | 0.5 (0.4–0.6)                 | <0.001  | 0.4 (0.3–0.5)                                       | <0.001  |
| Adenovirus                              | 93/601 (15.5)         | 460/1908 (24.1)       | 0.6 (0.5–0.7)                 | <0.001  |                                                     |         |
| Enterovirus                             | 35/601 (5.8)          | 142/1908 (7.4)        | 0.8 (0.5–1.1)                 | 0.168   | 0.6 (0.4–0.9)                                       |         |
| Human metapneumovirus                   | 5/601 (0.8)           | 115/1908 (6.0)        | 0.1 (0.05–0.3)                | <0.001  | 0.1 (0.04–0.3)                                      | <0.001  |
| Parainfluenza virus types 1, 2, 3       | 10/601 (1.7)          | 168/1908 (8.8)        | 0.2 (0.1–0.3)                 | <0.001  | 0.2 (0.1–0.5)                                       | 0.003   |

Note: Bold emphasizes statistically significant variables.
CI = confidence interval; ICU = intensive care unit; n/N = sample size/population size.
4 | DISCUSSION

Similar to previous studies conducted in South Africa and other temperate climates, low levels of HRSV activity occurred year-round in individuals admitted for SRI over the 4-year surveillance period with peaks of activity occurring between the autumn and early winter months. In 2012, higher year-round as well as an additional peak of HRSV activity during the September–December period (Spring–Summer) was observed at Edendale Hospital, which is in the subtropical climate of the KwaZulu-Natal Province. This is consistent with previous observations in tropical and subtropical climates, which demonstrate year round activity with some seasonal peaks, which may not be consistent over consecutive years.

In patients with SRI, prevalence of HRSV-associated illness was 23.9% (601/2509) and 3.9% (171/4399), respectively, in patients aged <5 and ≥5 years showing trends consistent with previous South African SARI studies (27% and 4% prevalence in children [<5 years] and adults [>18 years], respectively). Among children aged <5 years, HRSV-infected patients were more likely to have fever (≥38°C), cough, and the requirement for supplemental oxygen but were less likely to be malnourished, HIV-infected, admitted to ICU, or have respiratory virus coinfections. Within the <5 years age group, we also showed that HRSV-infected children aged ≥3 months were more likely to present with fever when compared to children aged <3 months. This corroborates previous findings that inclusion of fever in the SARI/SRI case definition could limit HRSV case detection among young children hospitalized with lower respiratory tract infection. Moderate to late preterm infants born at 33–35 weeks gestational age have previously also been shown to require supplemental oxygen during HRSV infection and admission to the ICU. The decreased likelihood of ICU admission for HRSV-positive patients aged <5 years observed in this study seems counterintuitive but studies that have shown an increased likelihood have done so in populations with a high prevalence of underlying disorders. Previous studies from South Africa reported that respiratory virus coinfection in children aged <5 years with HRSV-associated SRI was unlikely. Individuals in the ≥5-year age group with HRSV-associated SRI, on the contrary, were more likely to be HIV infected, consistent with higher HIV prevalence in these age groups. As both humoral and cellular immunity are required to control acute HRSV infections, an increased likelihood of HRSV infection in ≥5 year HIV-infected individuals may stem from an HIV-directed impairment of host immunity, while in the <5 year age group, it is likely that HRSV infection is driven by HRSV-naïve immune systems. Moyes et al. showed that HRSV-infected patients (<5 years) with SARI who were HIV-infected demonstrate a threefold to fivefold increased odds of hospitalization, higher odds of death, and increased length of hospitalization when compared with HIV-negative children.

Similar to previous studies, we demonstrated dynamic HRSV subgroup prevalence characterized by the cocirculation and year-on-year changes in the prevalence of each subgroup but favoring HRSV A (2012: 69%, 2013: 90%, 2014: 46%, and 2015: 68%) as the most dominant subgroup in most years. While some studies have shown a trend toward HRSV A causing more severe clinical outcomes when compared with HRSV B, there is currently no consensus. In our study, most clinical presentations or outcomes, underlying medical conditions, and coinfection variables demonstrated no statistically
**TABLE 2** Factors associated with HRSV infection among patients aged ≥5 years, hospitalized with severe respiratory illness, Edendale and Klerksdorp-Tshepong hospitals, South Africa, 2012–2015

| Characteristic                          | HRSV positive n/N (%) (N = 171) | HRSV negative n/N (%) | Univariate odds ratio (95% CI) | p value | Multivariable adjusted odds ratio (95% CI) years | p value |
|----------------------------------------|---------------------------------|-----------------------|-------------------------------|---------|-----------------------------------------------|---------|
| Total                                   | 171/4399 (3.9)                  | 4228/4399 (96.1)      | Reference                     |         | Reference                                    |         |
| Age                                     |                                 |                       |                               |         |                                               |         |
| 5–24 years                              | 38/171 (22.2)                   | 562/4228 (13.3)       | 0.6 (0.4–0.9)                 | 0.007   | 0.6 (0.4–0.9)                                 | 0.008   |
| 25–44 years                             | 82/171 (48.0)                   | 2094/4228 (49.5)      |                                |         |                                               |         |
| 45–64 years                             | 39/171 (22.8)                   | 1226/4228 (29.0)      | 0.5 (0.3–0.7)                 | 0.001   | 0.5 (0.3–0.9)                                 | 0.010   |
| 65+ years                               | 12/171 (7.0)                    | 346/4228 (8.2)        | 0.5 (0.3–0.9)                 | 0.048   | 0.8 (0.4–1.7)                                 | 0.606   |
| Female                                  | 102/170 (60)                    | 2219/4220 (52.6)      | 1.4 (0.9–1.8)                 | 0.060   |                                               |         |
| Year                                    |                                 |                       |                               |         |                                               |         |
| 2012                                    | 86/171 (50.3)                   | 1487/4230 (35.2)      | Reference                     |         | Reference                                    |         |
| 2013                                    | 49/171 (28.7)                   | 1128/4230 (26.7)      | 0.8 (0.5–1.1)                 | 0.118   | 0.8 (0.5–1.1)                                 | 0.160   |
| 2014                                    | 17/171 (9.9)                    | 836/4230 (19.8)       | 0.4 (0.2–0.6)                 | <0.001  | 0.4 (0.2–0.6)                                 | <0.001  |
| 2015                                    | 19/171 (11.1)                   | 779/4230 (18.4)       | 0.4 (0.3–0.7)                 | 0.001   | 0.5 (0.3–0.8)                                 | 0.009   |
| Clinical presentation and course        |                                 |                       |                               |         |                                               |         |
| Fever ≥38°C                             | 69/169 (40.8)                   | 1688/4197 (40.2)      | 1.0 (0.8–1.4)                 | 0.874   |                                               |         |
| Cough                                   | 128/148 (86.5)                  | 3503/3833 (91.4)      | 0.6 (0.4–0.9)                 | 0.053   |                                               |         |
| Supplemental oxygen needed              | 74/170 (43.5)                   | 1562/4147 (37.7)      | 1.3 (0.9–1.7)                 | 0.126   |                                               |         |
| Prolonged hospitalization (≥5 days)     | 117/171 (68.4)                  | 2848/4230 (67.3)      | 1.1 (0.8–1.5)                 | 0.765   |                                               |         |
| In-hospital death                       | 19/162 (11.7)                   | 485/4106 (11.8)       | 0.9 (0.6–1.6)                 | 0.974   |                                               |         |
| Admitted to ICU                         | 1/169 (0.6)                     | 21/4144 (0.5)         | 1.2 (0.2–8.7)                 | 0.882   |                                               |         |
| Tachypnea                               | 2/4 (50)                        | 6/22 (27.3)           | 2.7 (0.3–23.4)                | 0.380   |                                               |         |
| Stridor                                 | 0/4 (0)                         | 3/22 (13.6)           |                               |         |                                               |         |
| Underlying medical conditions           |                                 |                       |                               |         |                                               |         |
| HIV infection                           | 125/156 (80.1)                  | 2943/3966 (74.2)      | 1.4 (0.9–2.1)                 | 0.088   | 1.6 (1.0–2.6)                                 | 0.033   |
| Heart disease                           | 3/170 (1.8)                     | 72/4222 (1.7)         | 1.0 (0.3–3.3)                 | 0.954   |                                               |         |
| Chronic lung disease                    | 0/170 (0)                       | 28/4222 (0.7)         |                               |         |                                               |         |
| Asthma                                  | 7/170 (4.1)                     | 142/4222 (3.4)        | 1.2 (0.6–2.7)                 | 0.606   |                                               |         |
| Coinfection                             |                                 |                       |                               |         |                                               |         |
| Tuberculosis                            | 18/101 (17.8)                   | 653/2706 (24.1)       | 0.7 (0.4–1.1)                 | 0.132   |                                               |         |
| Streptococcus pneumoniae                | 21/162 (13.0)                   | 465/3965 (11.7)       | 1.1 (0.7–1.8)                 | 0.637   |                                               |         |
| Influenza                               | 7/171 (4.1)                     | 185/4230 (4.4)        | 0.9 (0.4–2.0)                 | 0.859   |                                               |         |
| Rhinovirus                              | 33/171 (19.3)                   | 693/4230 (16.4)       | 1.2 (0.8–1.8)                 | 0.324   |                                               |         |
| Adenovirus                              | 27/171 (15.8)                   | 296/4230 (7.0)        | 2.5 (1.6–3.8)                 | <0.001  |                                               |         |
| Enterovirus                             | 10/171 (5.8)                    | 35/4230 (0.8)         | 7.4 (3.6–15.3)                | <0.001  | 7.3 (3.4–15.7)                                | <0.001  |
| Human metapneumovirus                   | 2/171 (1.2)                     | 46/4230 (1.1)         | 1.1 (0.3–4.5)                 | 0.920   |                                               |         |
| Parainfluenza virus types 1, 2, 3       | 1/171 (0.6)                     | 86/4230 (2.0)         | 0.3 (0.04–2.04)               | 0.119   |                                               |         |

Note: Bold emphasizes statistically significant variables.
CI = confidence interval; ICU = intensive care unit; n/N = sample size/population size.

**significant association** with the detection of HRSV subgroups in patients. In our study, persons aged <5 years with HRSV A-related illness were more likely be coinfected with *S. pneumoniae* when compared with HRSV B. While the literature does not report on an association between *S. pneumoniae* and HRSV subgroup-specific infection, children hospitalized with HRSV infection and *S. pneumoniae* codetection in the nasopharynx have demonstrated worse clinical severity than those infected with HRSV only.46–48
## TABLE 3 Factors associated with HRSV subgroups among children aged <5 years, hospitalized with severe respiratory illness, Edendale and Klerksdorp-Tshepong hospitals, South Africa, 2012–2015

| Characteristic | HRSV subgroup n/ N (%) | HRSV A subgroup Samples positive/samples tested (%) | HRSV B subgroup Samples positive/samples tested (%) | Univariate odds ratio (95% CI) | p value | Multivariable adjusted odds ratio (95% CI) | p value |
|----------------|------------------------|---------------------------------------------------|---------------------------------------------------|-------------------------------|--------|------------------------------------------|--------|
| Total          | 449/601 (74.7)         | 319/449 (71.0)                                     | 130/449 (29.0)                                    |                               |        |                                          |        |
| Age            |                        |                                                   |                                                   |                               |        |                                          |        |
| <3 months      | 165/449 (36.7)         | 115/319 (36.1)                                     | 50/130 (38.5)                                     | 1.1 (0.7–1.9)                 | 0.637  |                                          |        |
| 3–5 months     | 105/449 (23.4)         | 76/319 (23.8)                                      | 29/130 (22.3)                                     | 1.5 (0.8–2.9)                 | 0.185  |                                          |        |
| 6–11 months    | 77/449 (17.1)          | 60/319 (18.8)                                      | 17/130 (13.1)                                     | 1.1 (0.6–2.0)                 | 0.852  |                                          |        |
| 12–23 months   | 52/449 (11.6)          | 44/319 (13.8)                                      | 18/130 (13.8)                                     | 0.7 (0.3–1.3)                 | 0.241  |                                          |        |
| 24–59 months   | 40/449 (8.9)           | 24/319 (7.5)                                       | 16/130 (12.3)                                     | 0.9 (0.6–1.3)                 | 0.442  |                                          |        |
| Female         | 198/449 (44.1)         | 137/319 (42.9)                                     | 61/130 (46.9)                                     | 0.9 (0.6–1.3)                 |        |                                          |        |
| Year           |                        |                                                   |                                                   |                               |        |                                          |        |
| 2012           | 122/449 (27.2)         | 87/319 (27.3)                                      | 35/130 (26.9)                                     | Reference                     |        | Reference                                 |        |
| 2013           | 139/449 (31.0)         | 125/319 (39.2)                                     | 14/130 (10.8)                                     | 3.6 (1.8–7.1)                 | <0.001 | 5.2 (2.0–13.3)                            | 0.001  |
| 2014           | 86/449 (19.2)          | 40/319 (12.5)                                      | 46/130 (35.4)                                     | 0.3 (0.2–0.6)                 | <0.001 | 0.5 (0.2–0.9)                            | 0.027  |
| 2015           | 102/449 (22.7)         | 67/319 (21.0)                                      | 35/130 (26.9)                                     | 0.8 (0.4–1.4)                 | 0.366  | 0.8 (0.4–1.6)                            | 0.535  |
| Clinical presentation and course | | | | | | | |
| Fever ≥38°C    | 275/448 (61.4)         | 192/319 (60.2)                                     | 83/129 (64.3)                                     | 0.8 (0.5–1.3)                 | 0.412  |                                          |        |
| Cough          | 439/447 (98.2)         | 311/317 (98.1)                                     | 128/130 (98.5)                                    | 0.8 (0.2–4.1)                 | 0.795  |                                          |        |
| Supplemental oxygen needed | 310/449 (69.0) | 222/319 (69.6) | 88/130 (67.7) | 1.1 (0.7–1.7) | 0.694 | | |
| Prolonged hospitalization (>5 days) | 226/449 (50.3) | 162/319 (50.8) | 64/130 (49.2) | 1.1 (0.7–1.6) | 0.765 | | |
| In-hospital death | 3/448 (0.7) | 3/319 (0.9) | 0/130 (0) | | | | |
| Admitted to ICU | 16/449 (3.6) | 8/319 (2.5) | 8/130 (6.2) | 0.4 (0.1–1.1) | 0.072 | | |
| Tachypnea | 249/447 (55.7) | 173/317 (54.6) | 76/130 (58.5) | 0.9 (0.6–1.3) | 0.452 | | |
| Stridor | 88/447 (19.7) | 63/317 (19.9) | 25/130 (19.2) | 1.0 (0.6–1.7) | 0.876 | | |
| Underlying medical conditions | | | | | | | |
| HIV infection | 21/417 (5.0) | 12/297 (4.0) | 9/120 (7.5) | 0.5 (0.2–1.3) | 0.158 | | |
| Prematurity | 52/449 (11.6) | 40/319 (12.5) | 12/130 (9.2) | 1.4 (0.7–2.8) | 0.311 | | |
| Heart disease | 1/449 (0.2) | 0/319 (0) | 1/130 (0.8) | | | | |
| Malnutrition | 70/405 (17.3) | 52/297 (17.5) | 18/108 (16.7) | 1.1 (0.6–1.9) | 0.843 | | |
| Chronic lung disease | 1/449 (0.22) | 0/319 (0) | 1/130 (0.8) | | | | |
| Asthma | 3/449 (0.7) | 3/319 (0.9) | 0/130 (0) | | | | |
| Coinfection | | | | | | | |
| Tuberculosis | 4/121 (3.3) | 4/93 (4.3) | 0/28 (0) | | | | |
| Streptococcus pneumoniae | 25/298 (8.4) | 23/208 (11.1) | 2/90 (2.2) | 5.5 (1.3–23.7) | 0.005 | 5.7 (1.3–25.6) | 0.024 |
| Influenza | 7/449 (1.6) | 5/319 (1.6) | 2/130 (1.5) | 1.0 (0.2–5.3) | 0.982 | | |
| Rhinovirus | 113/449 (25.2) | 79/319 (24.8) | 34/130 (26.2) | 0.9 (0.6–1.5) | 0.759 | | |
| Adenovirus | 64/449 (14.3) | 48/319 (15.0) | 16/130 (12.3) | 1.3 (0.7–2.3) | 0.446 | | |
| Enterovirus | 20/449 (4.5) | 16/319 (5.0) | 4/130 (3.1) | 1.7 (0.5–5.1) | 0.350 | | |

(Continues)
We identified four circulating HRSV genotypes over the observation period, HRSV A: NA1 and ON1 and HRSV B: BA9 and BA10. Following global trends, the emergent HRSV A genotype, ON1, showed a gradual increase in prevalence from 5.6% (3/53) in 2012 to 81.5% (22/27) in 2015. A complete replacement of the previously dominant HRSV A, NA1 genotype was not found as noted in several studies. Three separate lineages of the ON1 genotype 1.1, 1.2, and 1.3 are circulating, and studies have suggested that the 1.1 lineage emerged prior to the other lineages. Circulation of the 1.1 lineage was also previously observed in South Africa in 2011–2012. Here, we demonstrated the cocirculation of all three ON1 lineages in South Africa, as observed in most other countries that have conducted HRSV surveillance over two consecutive seasons since ON1 emergence. As with HRSV subgroups, prior studies have shown a spectrum of clinical outcomes associated with ON1 genotype infection. We found no association with clinical outcomes when comparing NA1 with ON1 genotypes. HRSV B genotype BA10 showed a gradual shift in prevalence from 33.3% (2/6) in 2012 to 78.6% (11/14) in 2015, albeit using limited study numbers.

This study was limited by only including individuals that were admitted to two sentinel SRI surveillance sites in the KwaZulu-Natal and North-West Provinces of South Africa. It is therefore possible that our study may not be an accurate representation of the general South African population or HRSV subgroup and genotype prevalence. In addition, only 23% (175/772) of the HRSV-positive samples were genotyped. We therefore may not have shown the full diversity of HRSV genotypes circulating within the country. Furthermore, when we reviewed subgroup/genotype prevalence data available from other South African surveillance programs, the dominance patterns were the same (data not shown). Restricted study sampling may also have limited our ability to find statistically significant associations between measured variables and HRSV genotypes in all age groups and with HRSV subgroups in the ≥5-year age group. It is therefore recommended that future studies in South Africa continue to follow HRSV prevalence and diversity trends in all age groups to ascertain the target populations for candidate vaccines. In these studies, a greater emphasis should be placed on sampling broadly across the population and genotyping a larger proportion of the HRSV-positive samples.
FIGURE 3  Inferred phylogeny of human respiratory syncytial virus (HRSV) A G-gene second variable domain of south African HRSV A isolates (red triangles) based on maximum likelihood model (Mega 5.0 under GTR GAMMA model of nucleotide evolution). Selected publicly available sequences global HRSV A sequences are represented by GenBank accession numbers (blue circles). Brackets indicate HRSV NA1 and ON1 (1.1, 1.2, and 1.3) lineages. Sample dates indicated by last 4 digits of sample names.
### TABLE 4 Factors associated with HRSV A genotypes among patients aged <5 years, hospitalized with severe respiratory illness, Edendale and Klerksdorp-Tshepong hospitals, South Africa, 2012–2015

| Characteristic                              | HRSV genotyped n/N (%) | NA1 genotype Samples positive/samples tested (%) | ON1 genotype Samples positive/samples tested (%) | Univariate odds ratio (95% CI) | p value |
|---------------------------------------------|------------------------|-----------------------------------------------|-----------------------------------------------|--------------------------------|---------|
| **Total**                                   | 135/319 (42.3)         | 104/135 (77.0)                               | 31/135 (23.0)                                 |                               |         |
| **Age**                                     |                        |                                               |                                               |                               |         |
| <3 months                                   | 53/135 (39.3)          | 41/104 (39.4)                                | 12/31 (38.7)                                  |                               |         |
| 3–5 months                                  | 35/135 (25.9)          | 28/104 (26.9)                                | 7/31 (22.6)                                   | 0.8 (0.3–2.4)                  | 0.768   |
| 6–11 months                                 | 23/135 (17.0)          | 18/104 (17.3)                                | 5/31 (16.1)                                   | 0.9 (0.3–3.1)                  | 0.931   |
| 12–23 months                                | 14/135 (10.4)          | 10/104 (9.6)                                 | 4/31 (12.9)                                   | 1.4 (0.4–5.2)                  | 0.644   |
| 24–59 months                                | 10/135 (7.4)           | 7/104 (6.7)                                  | 3/31 (9.7)                                    | 1.5 (0.3–6.6)                  | 0.618   |
| **Female**                                  | 62/135 (45.9)          | 52/104 (50.0)                                | 10/31 (32.3)                                  | 0.5 (0.2–1.1)                  | 0.079   |
| **Year**                                    |                        |                                               |                                               |                               |         |
| 2012                                        | 50/135 (37.0)          | 47/104 (45.2)                                | 3/31 (9.7)                                    |                               |         |
| 2013                                        | 61/135 (45.2)          | 54/104 (51.9)                                | 7/31 (22.6)                                   | 2.0 (0.5–8.3)                  | 0.324   |
| 2015                                        | 24/135 (17.8)          | 3/104 (2.9)                                  | 21/31 (67.7)                                  | 109.7 (20.4–588.9)            | <0.001  |
| **Clinical presentation and course**        |                        |                                               |                                               |                               |         |
| Fever ≥38°C                                  | 82/135 (60.7)          | 63/104 (60.6)                                | 19/31 (61.3)                                  | 1.0 (0.5–2.3)                  | 0.943   |
| Cough                                       | 132/134 (98.5)         | 102/103 (99.0)                               | 30/31 (96.8)                                  | 0.3 (0.2–4.8)                  | 0.405   |
| Supplemental oxygen needed                   | 91/134 (67.9)          | 72/103 (69.9)                                | 19/31 (61.3)                                  | 0.7 (0.3–1.6)                  | 0.373   |
| Prolonged hospitalization (≥5 days)         | 73/135 (54.1)          | 62/104 (59.6)                                | 11/31 (35.5)                                  | 0.4 (0.2–0.9)                  | 0.018   |
| In-hospital death                           | 2/133 (1.5)            | 1/102 (0.98)                                 | 1/31 (3.2)                                    | 3.4 (0.2–55.5)                 | 0.408   |
| Admitted to ICU                             | 1/134 (0.75)           | 1/103 (0.97)                                 | 0/31 (0)                                      |                               |         |
| Tachypnea                                   | 79/134 (59.0)          | 60/103 (58.3)                                | 19/31 (61.3)                                  | 1.1 (0.5–2.6)                  | 0.762   |
| Stridor                                     | 29/134 (21.6)          | 26/103 (25.2)                                | 3/31 (9.7)                                    | 0.3 (0.1–1.1)                  | 0.049   |
| **Underlying medical conditions**           |                        |                                               |                                               |                               |         |
| HIV infection                                | 5/123 (4.1)            | 5/94 (5.3)                                   | 0/29 (0)                                      |                               |         |
| Prematurity                                  | 14/135 (10.4)          | 12/104 (11.5)                                | 2/31 (6.5)                                    | 0.5 (0.1–2.5)                  | 0.392   |
| Heart disease                               | 0/135 (0)              |                                               |                                               |                               |         |
| Malnutrition                                | 25/132 (18.9)          | 21/101 (20.8)                                | 4/31 (12.9)                                   | 0.6 (0.2–1.8)                  | 0.311   |
| Chronic lung disease                        | 0/135 (0)              |                                               |                                               |                               |         |
| Asthma                                      | 1/135 (0.7)            | 0/104 (0)                                    | 1/31 (3.2)                                    |                               |         |
| **Coinfection**                              |                        |                                               |                                               |                               |         |
| Tuberculosis                                 | 1/35 (2.9)             | 1/27 (3.7)                                   | 0/8 (0)                                       |                               |         |
| Streptococcus pneumoniae                    | 8/83 (9.6)             | 6/66 (9.1)                                   | 2/17 (11.8)                                   | 1.3 (0.2–7.3)                  | 0.745   |
| Influenza                                   | 1/135 (0.7)            | 1/104 (1.0)                                  | 0/31 (0)                                      |                               |         |
| Rhinovirus                                  | 39/135 (28.9)          | 32/104 (30.8)                                | 7/31 (22.6)                                   | 0.7 (0.3–1.7)                  | 0.369   |
| Adenovirus                                  | 22/135 (16.3)          | 21/104 (20.2)                                | 1/31 (3.2)                                    | 0.1 (0.02–1.02)                | 0.010   |
| Enterovirus                                 | 5/135 (3.7)            | 4/104 (3.8)                                  | 1/31 (3.2)                                    | 0.8 (0.1–7.7)                  | 0.871   |
| Human metapneumovirus                       | 1/135 (0.7)            | 1/104 (1.0)                                  | 0/31 (0)                                      |                               |         |
| Parainfluenza virus types 1, 2, 3           | 1/135 (0.7)            | 0/104 (0)                                    | 1/31 (3.2)                                    |                               |         |

Note: CI = confidence interval; ICU = intensive care unit; n/N = sample size/population size.
5 | CONCLUSION

This study builds upon our understanding of the clinical and epidemiological relevance of HRSV, its subgroups, and genotypes among patients hospitalized with SRI in South Africa. Changes in HRSV diversity over the study period demonstrated the presence and dominance of similar subgroups and genotypes found elsewhere in the world. This may suggest that no region-specific considerations will be required when selecting appropriate vaccine target strains. Furthermore, we showed that the youngest age group (<6 months), which demonstrated the highest HRSV infection prevalence (47%) would benefit most from HRSV vaccine implementation, similar to findings from previous studies from South Africa (55%). While no significant differences were found between the clinical outcomes and underlying illnesses associated with HRSV A and B infection or between HRSV A genotypes NA1 and ON1, a statistically significant association between HRSV A and S. pneumoniae coinfection in young children warrants further investigation of disease outcomes.

DISCLAIMER
The findings and conclusions in this report are those of the author(s) and do not necessarily represent the official position of the funding agencies.

ACKNOWLEDGMENTS
We would like to thank the SRI surveillance teams in Edendale and Klerksdorp-Tshepong Hospitals for their contributions to this study. This work was supported by funds from the United States Centers for Disease Control and Prevention (CDC), Atlanta, Georgia; cooperative agreements 5U19GH000622 and 5U51IP000528.

CONFLICT OF INTEREST
Cheryl Cohen has received funding to her institution from Sanofi Pasteur, US Centers for Disease Control and Prevention, World Health Organization, and has received funding to attend a meeting from Parexel. Dr. Dawood reports personal fees from Pfizer-South Africa and conference attendance sponsorship from MSD-South Africa, Pfizer-South Africa, and Biomiereux-South Africa.

AUTHOR CONTRIBUTIONS
Ziyaad Valley-Omar: Conceptualization; data curation; formal analysis; investigation; methodology; project administration. Stefano Tempia: Conceptualization; data curation; formal analysis; investigation; methodology; project administration; resources. Orienka Hellferscee: Conceptualization; data curation; methodology; project administration; supervision. Anne von Gottberg: Conceptualization; investigation; project administration; supervision. Cheryl Cohen: Conceptualization; project administration; resources; supervision.

PRESENTATION OF DATA
Data from this study were presented as a poster at the 11th International Respiratory Syncytial Virus Symposium, November 2018, Ashville, NC, USA (Abstract number: ARSVA0113).

PEER REVIEW
The peer review history for this article is available at https://publons.com/publon/10.1111/irv.12905.

DATA AVAILABILITY STATEMENT
Sequences with the following accession numbers MNS16831 to MN517111 were uploaded to GenBank.

ORCID
Ziyaad Valley-Omar https://orcid.org/0000-0003-4804-3774
Stefano Tempia https://orcid.org/0000-0003-4395-347X
Orienka Hellferscee https://orcid.org/0000-0001-9246-8927
Sibongile Walaza https://orcid.org/0000-0001-7588-2480
Meredith McMorrow https://orcid.org/0000-0001-6363-4033
Cheryl Cohen https://orcid.org/0000-0003-0376-2302

REFERENCES
1. Shi T, McAllister DA, O’Brien KL, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet. 2017;390(10098):946-958.
2. Moyes J, Cohen C, Pretorius M, et al. Epidemiology of respiratory syncytial virus-associated acute lower respiratory tract infection hospitalizations among HIV-infected and HIV-uninfected South African children, 2010-2011. J Infect Dis. 2013;208(Suppl 3):S217-S226.
3. Moyes J, Walaza S, Pretorius M, et al. Respiratory syncytial virus in adults with severe acute respiratory illness in a high HIV prevalence setting. J Infect. 2017;75(4):346-355.
4. Eshaghi A, Duvvuri VR, Lai R, et al. Genetic variability of human respiratory syncytial virus A strains circulating in Ontario: a novel genotype with a 72 nucleotide G gene duplication. PloS One. 2012; 7(3):e32807.
5. Khor CS, Sam IC, Hooi PS, Chan YF. Displacement of predominant respiratory syncytial virus genotypes in Malaysia between 1989 and 2011. Infection, Genetics and Evolution: Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases. 2013;14:357-360.
6. Peret TC, Hall CB, Hammond GW, et al. Circulation patterns of group A and B human respiratory syncytial virus genotypes in 5 communities in North America. J Infect Dis. 2000;181(6):1893-1896.
7. Trento A, Casas I, Calderon A, et al. Ten years of global evolution of the human respiratory syncytial virus BA genotype with a 60-nucleotide duplication in the G gene protein. J Virol. 2010;84(15):7500-7512.
8. Agoti CN, Otieno JR, Gitahi CW, Cane PA, Nokes DJ. Rapid spread and diversification of respiratory syncytial virus genotype ON1. *Emerg Infect Dis*. 2014;20(6):950-959.

9. Hirano E, Kobayashi M, Tsukagoshi H, et al. Molecular evolution of human respiratory syncytial virus attachment glycoprotein (G) gene of new genotype ON1 and ancestor NA1. *Infection, Genetics and Evolution: Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases*. 2014;28:183-191.

10. Valley-Omar Z, Muloiwa R, Hu NC, Eley B, Hsiao NY. Novel respiratory syncytial virus subtype ON1 among children, Cape Town, South Africa, 2012. *Emerg Infect Dis*. 2013;19(4):668-670.

11. Yoshihara K, le MN, Nagasawa K, et al. Molecular evolution of respiratory syncytial virus subgroup A genotype NA1 and ON1 attachment glycoprotein (G) gene in central Vietnam. *Infection, Genetics and Evolution: Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases*. 2016;45:437-446.

12. Mejias A, Rodriguez-Fernandez R, Peeples ME, Ramilo O. Circulation of previously circulating respiratory syncytial virus A ON1 genotype: global and local transmission dynamics. *Sci Rep*. 2015;5(1):14268.

13. Esposito S, Piralla A, Zampiero A, et al. Characteristics and their clinical relevance of respiratory syncytial virus types and genotypes circulating in northern Italy in five consecutive winter seasons. *PloS One*. 2015;10(6):e0129369.

14. Van Niekerk S, Venter M. Replacement of previously circulating respiratory syncytial virus subtype ON1 among children, Cape Town, South Africa, 2012. *Emerg Infect Dis*. 2013;19(4):668-670.

15. Pretorius MA, Tempia S, Moyes J, et al. The effects of the attributable fraction and the duration of symptoms on burden estimates of influenza-associated respiratory illnesses in a high HIV prevalence setting, South Africa, 2013–2015. *Influenza Other Respi Viruses*. 2018;12(3):360-373.

16. Pretorius MA, Madhi SA, Cohen C, et al. Viral respiratory coinfections identified by a 10-plex real-time reverse-transcription polymerase chain reaction assay in patients hospitalized with severe acute respiratory illness—South Africa, 2009–2010. *J Infect Dis*. 2012;206(Suppl 3):S159-S165.

17. Hu A, Colella M, Tam JS, Rappaport R, Cheng SM. Simultaneous detection, subgrouping, and quantitation of respiratory syncytial virus A and B by real-time PCR. *J Clin Microbiol*. 2003;41(1):149-154.

18. van de Pol AC, Wolfs TF, van Loon AM, et al. Molecular quantification of respiratory syncytial virus in respiratory samples: reliable detection during the initial phase of infection. *J Clin Microbiol*. 2010;48(10):3569-3574.

19. Sullender WM, Sun L, Anderson LJ. Analysis of respiratory syncytial virus genetic variability with amplified cDNAs. *J Clin Microbiol*. 1993;31(5):1224-1231.

20. Welliver RC. Sr. Temperature, humidity, and ultraviolet B radiation predict community respiratory syncytial virus activity. *Pediatr Infect Dis J*. 2007;26(11 Suppl):S29-S35.

21. Lam TT, Tang JY, Lai FY, et al. Comparative global epidemiology of influenza, respiratory syncytial and parainfluenza viruses, 2010–2015. *J Infect*. 2019;79(4):373-382.

22. Edgar RC. MUSCLE: multiple sequence alignment with high accuracy and high throughput. *Nucleic Acids Res*. 2004;32(5):1792-1797.

23. Stamatakis A. RAxML version 8: a tool for phylogenetic analysis and post-analysis of large phylogenies. *Bioinformatics*. 2014;30(9):1312-1313.

24. Rha B, Dahl RM, Moyes J, et al. Performance of surveillance case definitions in detecting respiratory syncytial virus infection among young children hospitalized with severe respiratory illness—South Africa, 2009–2014. *Journal of the Pediatric Infectious Diseases Society*. 2019;8(4):325-333.
44. Papadopoulos NG, Gourgiotis D, Javadyan A, et al. Does respiratory syncytial virus subtype influence the severity of acute bronchiolitis in hospitalized infants? *Respir Med*. 2004;98(9):879-882.

45. Walsh EE, McConnochie KM, Long CE, Hall CB. Severity of respiratory syncytial virus infection is related to virus strain. *J Infect Dis*. 1997;175(4):814-820.

46. Brealey JC, Chappell KJ, Galbraith S, et al. Streptococcus pneumoniae colonization of the nasopharynx is associated with increased severity during respiratory syncytial virus infection in young children. *Respirology*. 2018;23(2):220-227.

47. Smith CM, Sandrini S, Datta S, et al. Respiratory syncytial virus increases the virulence of Streptococcus pneumoniae by binding to penicillin binding protein 1a. A new paradigm in respiratory infection. *Am J Respir Crit Care Med*. 2014;190(2):196-207.

48. Weinberger DM, Klugman KP, Steiner CA, Simonsen L, Viboud C. Association between respiratory syncytial virus activity and pneumococcal disease in infants: a time series analysis of US hospitalization data. *PloS Med*. 2015;12(1):e1001776.

49. Abadom TR, Smith AD, Tempia S, Madhi SA, Cohen C, Cohen AL. Risk factors associated with hospitalisation for influenza-associated severe acute respiratory illness in South Africa: a case-population study. *Vaccine*. 2016;34(46):5649-5655.

50. Hall CB, Weinberg GA, Iwane MK, et al. The burden of respiratory syncytial virus infection in young children. *N Engl J Med*. 2009;360(6):588-598.

**SUPPORTING INFORMATION**

Additional supporting information may be found in the online version of the article at the publisher's website.

**How to cite this article:** Valley-Omar Z, Tempia S, Hellferssee O, et al. Human respiratory syncytial virus diversity and epidemiology among patients hospitalized with severe respiratory illness in South Africa, 2012–2015. *Influenza Other Respi Viruses*. 2022;16(2):222-235. doi: 10.1111/irv.12905